Nifib (Nintedanib)

Nintedanib inhibits several receptor tyrosine kinases, notably VEGFR, PDGFR and FGFR. By blocking these receptors it reduces fibroblast activation, angiogenesis and extracellular matrix formation, which are key processes in fibrotic lung disease and tumor vascularisation.

The exact dose of Nifib is set by the prescribing clinician based on the specific indication, patient weight, liver function, concomitant medicines and overall clinical assessment. No fixed regimen can be provided without a qualified healthcare professional’s evaluation.

Safety data for nintedanib in pregnancy and lactation are limited. The product should only be used if the potential benefit justifies the potential risk to the fetus or infant, and the decision must be made by a qualified obstetric or pulmonary specialist.

To request Nifib, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Nifib belongs to the class of tyrosine kinase inhibitors, whereas other approved options include pirfenidone (an anti‑oxidant) and supportive care. Nifib’s mechanism targets multiple growth‑factor receptors, offering a broader anti‑fibrotic effect, but choice of therapy depends on individual patient factors and physician judgment.

Store Nifib tablets at ambient temperature, preferably below 25 °C. Keep the product in its original container, protect it from moisture and direct sunlight, and avoid storing in areas with high humidity or temperature fluctuations.

Nifib is taken orally, usually as a tablet swallowed whole with water. The exact timing (e.g., with food or on an empty stomach) and frequency are determined by the prescribing clinician and should follow the instructions on the prescription label.

Serious risks include significant liver enzyme elevations, which may indicate hepatic injury, and bleeding complications, especially in patients receiving anticoagulants or with a history of ulcers. Cardiovascular events such as hypertension or arterial thrombosis have also been reported and require monitoring.

Patients with severe hepatic impairment, uncontrolled bleeding disorders, or known hypersensitivity to nintedanib should avoid the drug. Additionally, individuals taking strong CYP3A4 inhibitors or those with contraindicated concomitant anticoagulant therapy should be evaluated carefully before initiation.